LIGAND PHARMACEUTICALS INC LGNZZ
OTC · OOTC · stock · Pharmaceutical Preparations
4/9
Piotroski F — financial health
6.75
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $268.1M | $124.5M | — | $48.9M | $1.0B |
| 2024 | $167.1M | -$4.0M | — | $95.2M | $830.4M |
| 2023 | $131.3M | $52.2M | — | $46.1M | $700.9M |
| 2022 | $196.2M | -$33.4M | — | $119.9M | $597.5M |
| 2021 | $241.5M | $57.1M | — | $70.0M | $821.2M |
| 2020 | $163.6M | -$3.0M | — | $50.1M | $709.5M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Sabba Stephen L | director | 2026-06-16 | Option exercise | 2,145 | $66.13 |
| Sabba Stephen L | director | 2026-06-16 | Sell | 2,145 | $254.00 |
| Haas Jason | director | 2026-06-12 | Option exercise | 3,000 | $51.56 |
| Haas Jason | director | 2026-06-12 | Sell | 3,000 | $255.01 |
| Haas Jason | director | 2026-06-12 | Option exercise | 1,000 | $51.56 |
| Haas Jason | director | 2026-06-12 | Sell | 3,461 | $256.08 |
| Aryeh Jason | director | 2026-06-11 | Sell | 4,500 | $250.00 |
| Aryeh Jason | director | 2026-06-10 | Sell | 500 | $250.00 |
Why these scores methodology →
Piotroski F-score: 4/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 6.75 (safe)
- Working capital / assets 0.509
- Retained earnings / assets 0.39
- EBIT / assets 0.026
- Equity / liabilities 1.872
Source: SEC EDGAR filings · CIK 0000886163 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.